PL2763690T3 - Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych - Google Patents
Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowychInfo
- Publication number
- PL2763690T3 PL2763690T3 PL12766695T PL12766695T PL2763690T3 PL 2763690 T3 PL2763690 T3 PL 2763690T3 PL 12766695 T PL12766695 T PL 12766695T PL 12766695 T PL12766695 T PL 12766695T PL 2763690 T3 PL2763690 T3 PL 2763690T3
- Authority
- PL
- Poland
- Prior art keywords
- lixisenatide
- stenosis
- obstruction
- treatment
- duct system
- Prior art date
Links
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 208000031481 Pathologic Constriction Diseases 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- 210000000277 pancreatic duct Anatomy 0.000 title 1
- 208000037804 stenosis Diseases 0.000 title 1
- 230000036262 stenosis Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183867 | 2011-10-04 | ||
| EP12766695.6A EP2763690B1 (en) | 2011-10-04 | 2012-10-02 | Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
| PCT/EP2012/069485 WO2013050379A1 (en) | 2011-10-04 | 2012-10-02 | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2763690T3 true PL2763690T3 (pl) | 2016-04-29 |
Family
ID=46963761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12766695T PL2763690T3 (pl) | 2011-10-04 | 2012-10-02 | Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130096060A1 (pl) |
| EP (1) | EP2763690B1 (pl) |
| CY (1) | CY1117394T1 (pl) |
| DK (1) | DK2763690T3 (pl) |
| ES (1) | ES2562651T3 (pl) |
| HR (1) | HRP20160171T1 (pl) |
| HU (1) | HUE028568T2 (pl) |
| PL (1) | PL2763690T3 (pl) |
| PT (1) | PT2763690E (pl) |
| SI (1) | SI2763690T1 (pl) |
| WO (1) | WO2013050379A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| PL2611458T3 (pl) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
| MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
| MX2016008978A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol. |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2022212271A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
| WO2025178387A1 (ko) * | 2024-02-20 | 2025-08-28 | 가천대학교 산학협력단 | Trpv1 활성 매개 질환 치료용 약학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2038597A1 (en) * | 1991-03-19 | 1992-09-20 | Jose P. Garzaran | A method and a pharmaceutical preparation for treating pain |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| ATE493998T1 (de) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | Pharmazeutische zusammensetzung mit einem exendin-4-peptid |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| DE122007000044I2 (de) | 1997-01-07 | 2011-05-05 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| ES2293688T5 (es) | 1997-08-08 | 2011-05-04 | Amylin Pharmaceuticals, Inc. | Nuevos compuestos análogos de la exendina. |
| MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
| ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2004005342A1 (en) | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| BR0314996A (pt) | 2002-10-02 | 2005-08-09 | Zealand Pharma As | Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada |
| EP1937297A2 (en) | 2005-09-08 | 2008-07-02 | Gastrotech Pharma A/S | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
-
2012
- 2012-10-02 PL PL12766695T patent/PL2763690T3/pl unknown
- 2012-10-02 ES ES12766695.6T patent/ES2562651T3/es active Active
- 2012-10-02 HU HUE12766695A patent/HUE028568T2/en unknown
- 2012-10-02 EP EP12766695.6A patent/EP2763690B1/en not_active Not-in-force
- 2012-10-02 HR HRP20160171TT patent/HRP20160171T1/hr unknown
- 2012-10-02 PT PT127666956T patent/PT2763690E/pt unknown
- 2012-10-02 DK DK12766695.6T patent/DK2763690T3/en active
- 2012-10-02 WO PCT/EP2012/069485 patent/WO2013050379A1/en not_active Ceased
- 2012-10-02 US US13/633,563 patent/US20130096060A1/en not_active Abandoned
- 2012-10-02 SI SI201230454T patent/SI2763690T1/sl unknown
-
2016
- 2016-02-24 CY CY20161100151T patent/CY1117394T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2763690E (pt) | 2016-03-23 |
| US20130096060A1 (en) | 2013-04-18 |
| WO2013050379A1 (en) | 2013-04-11 |
| SI2763690T1 (sl) | 2016-03-31 |
| ES2562651T3 (es) | 2016-03-07 |
| HUE028568T2 (en) | 2016-12-28 |
| DK2763690T3 (en) | 2016-02-15 |
| EP2763690A1 (en) | 2014-08-13 |
| CY1117394T1 (el) | 2017-04-26 |
| HRP20160171T1 (hr) | 2016-03-11 |
| EP2763690B1 (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2763690T1 (sl) | Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke | |
| GB2485291B (en) | Cannabidiol for use in the treatment of generalised and/or partial seizures | |
| ZA201206775B (en) | Pyridine and pyrazine derivative for the treatment of cf | |
| PT2740489T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático | |
| IL227762A0 (en) | Devices and methods for the treatment of blood vessels in body cavities | |
| PT2740793T (pt) | Composição de fármacos para o tratamento e/ou a prevenção de cancro | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| SMT201800064T1 (it) | Derivati di pirrolopirimidina per l'uso del trattamento di infezioni virali | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| IL221874A (en) | History of pyrimidine and their use in the treatment of respiratory diseases such as copd | |
| GB201415955D0 (en) | Medical devices and systems for manipulating foreign bodies and methods of using the same | |
| GB2503066B (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| PL2701645T3 (pl) | Urządzenie do leczenia i/lub zapobiegania chorobom rogówki | |
| IL225793A0 (en) | Methods and preparations for curing insulin-related medical conditions | |
| EP2934501A4 (en) | USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES | |
| IL222482A0 (en) | Methods and compositions for the treatment of fluid accumulation in and/or under the retina | |
| HUE045812T2 (hu) | Eljárás és berendezés tárgyak kezelésére | |
| PT2658536T (pt) | Gemcabeno e derivados para tratamento da pancreatite | |
| EP2559432A4 (en) | MEANS FOR THE PREVENTION AND TREATMENT OF ACUTE AND CHRONIC PANCREATITIS | |
| IL223219A0 (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | |
| SI2699545T1 (sl) | Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma | |
| PL2421520T3 (pl) | ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA | |
| IL210524A0 (en) | Formulations for treating and/or preventing black-line stains | |
| PT2389936E (pt) | Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca | |
| HU1000356D0 (en) | Quinoxaline derivatives and their use for the treatment of mycobacterial infections |